Acadia Pharmaceuticals (ACAD) Operating Leases (2019 - 2026)

Acadia Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $39.0 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 12.62% year-over-year to $39.0 million in Q1 2026; TTM through Mar 2026 was $39.0 million, a 12.62% decrease from a year earlier, with the FY2025 full-year figure at $40.6 million, down 3.53% from the prior year.
• Operating Leases fell to $39.0 million in Q1 2026 per ACAD's latest filing, from $40.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $55.5 million in Q1 2022 and bottomed at $39.0 million in Q1 2026.
• The 5-year median for Operating Leases is $47.8 million (2023), against an average of $47.3 million.
• Across the five-year window, Operating Leases fell 15.97% in 2024 and climbed 6.44% in 2025, its largest moves.
• Year by year, Operating Leases stood at $52.7 million in 2022, then slipped by 9.29% to $47.8 million in 2023, then fell by 12.06% to $42.0 million in 2024, then slipped by 3.53% to $40.6 million in 2025, then dropped by 3.82% to $39.0 million in 2026.
• Per Business Quant, the three latest ACAD Operating Leases figures stand at $39.0 million (Q1 2026), $40.6 million (Q4 2025), and $43.0 million (Q3 2025).